219 related articles for article (PubMed ID: 10980849)
1. Combination drug therapy for combined hyperlipidemia.
Guyton JR
Curr Cardiol Rep; 1999 Sep; 1(3):244-50. PubMed ID: 10980849
[TBL] [Abstract][Full Text] [Related]
2. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hyperlipidemia with combined niacin-statin regimens.
Guyton JR; Capuzzi DM
Am J Cardiol; 1998 Dec; 82(12A):82U-84U; discussion 85-86U. PubMed ID: 9915667
[TBL] [Abstract][Full Text] [Related]
4. Fibrates in combination with statins in the management of dyslipidemia.
Jacobson TA; Zimmerman FH
J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
[TBL] [Abstract][Full Text] [Related]
5. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
Jacobson TA
Curr Atheroscler Rep; 2001 Sep; 3(5):373-82. PubMed ID: 11487448
[TBL] [Abstract][Full Text] [Related]
6. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Yim BT; Chong PH
Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
8. LDL reduction: how low should we go and is it safe?
Robinson JG
Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
[TBL] [Abstract][Full Text] [Related]
9. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
[TBL] [Abstract][Full Text] [Related]
10. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.
Agouridis AP; Filippatos TD; Tsimihodimos V; Elisaf MS
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):355-66. PubMed ID: 21438815
[TBL] [Abstract][Full Text] [Related]
11. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
12. Treating dyslipidemic patients with lipid-modifying and combination therapies.
Worz CR; Bottorff M
Pharmacotherapy; 2003 May; 23(5):625-37. PubMed ID: 12741437
[TBL] [Abstract][Full Text] [Related]
13. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of antilipidemic agents: facts and fictions.
Xydakis AM; Jones PH
Curr Atheroscler Rep; 2003 Sep; 5(5):403-10. PubMed ID: 12911851
[No Abstract] [Full Text] [Related]
15. [Fibrate and statine myopathy].
Finsterer J
Nervenarzt; 2003 Feb; 74(2):115-22. PubMed ID: 12596012
[TBL] [Abstract][Full Text] [Related]
16. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
17. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
González Santos P
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
[TBL] [Abstract][Full Text] [Related]
18. Risk for myopathy with statin therapy in high-risk patients.
Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
[TBL] [Abstract][Full Text] [Related]
19. Nicotinic acid as a lipid-modifying drug--a review.
Julius U; Fischer S
Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
[TBL] [Abstract][Full Text] [Related]
20. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
